Disc Medicine, Inc. (IRON)
57.00
+1.26
(+2.26%)
USD |
NASDAQ |
Oct 15, 10:02
Disc Medicine Enterprise Value : 1.481B for Oct. 14, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 14, 2026 | 1.481B |
| October 13, 2026 | 1.513B |
| October 12, 2026 | 1.662B |
| October 09, 2026 | 1.723B |
| October 08, 2026 | 1.673B |
| October 07, 2026 | 1.689B |
| October 06, 2026 | 1.707B |
| October 05, 2026 | 1.772B |
| October 02, 2026 | 1.817B |
| October 01, 2026 | 1.782B |
| September 30, 2026 | 1.853B |
| September 29, 2026 | 1.869B |
| September 28, 2026 | 1.833B |
| September 25, 2026 | 1.845B |
| September 24, 2026 | 1.891B |
| September 23, 2026 | 1.877B |
| September 22, 2026 | 1.969B |
| September 21, 2026 | 1.969B |
| September 18, 2026 | 2.009B |
| September 17, 2026 | 1.996B |
| September 16, 2026 | 1.972B |
| September 15, 2026 | 1.924B |
| September 14, 2026 | 1.986B |
| September 11, 2026 | 2.030B |
| September 10, 2026 | 2.186B |
| Date | Value |
|---|---|
| September 09, 2026 | 2.277B |
| September 08, 2026 | 2.290B |
| September 04, 2026 | 2.381B |
| September 03, 2026 | 2.387B |
| September 02, 2026 | 2.413B |
| September 01, 2026 | 2.360B |
| August 31, 2026 | 2.359B |
| August 28, 2026 | 2.412B |
| August 27, 2026 | 2.509B |
| August 26, 2026 | 2.513B |
| August 25, 2026 | 2.503B |
| August 24, 2026 | 2.447B |
| August 21, 2026 | 2.403B |
| August 20, 2026 | 2.366B |
| August 19, 2026 | 2.423B |
| August 18, 2026 | 2.418B |
| August 17, 2026 | 2.413B |
| August 14, 2026 | 2.366B |
| August 13, 2026 | 2.411B |
| August 12, 2026 | 2.433B |
| August 11, 2026 | 2.457B |
| August 10, 2026 | 2.345B |
| August 07, 2026 | 2.313B |
| August 06, 2026 | 2.313B |
| August 05, 2026 | 2.369B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Recursion Pharmaceuticals, Inc. | 1.513B |
| Agenus, Inc. | 541.66M |
| Amgen, Inc. | 273.67B |
| Anika Therapeutics, Inc. | 257.84M |
| BioCryst Pharmaceuticals, Inc. | 2.538B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -59.53M |
| Total Expenses (Quarterly) | 59.53M |
| EPS Diluted (Quarterly) | -1.539 |
| Earnings Yield | -11.54% |
| Normalized Earnings Yield | -11.54 |